文献速递慢性肾脏病血液净化与透析

GLP-1RA对2型糖尿病患者肾脏结局的异质性治疗效果

Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes.
PubMed 文献 · Kidney Int · 2026-07-24

本研究采用目标试验模拟框架,在斯德哥尔摩纳入超过28,000例2型糖尿病起始GLP-1RA或DPP-4i的患者。与DPP-4i相比,GLP-1RA与五年肾脏结局风险降低相关(HR 0.84 [0.72-0.97]),但获益具有显著异质性,KFRE最高风险四分位患者绝对风险降低显著(-2.76%),而最低四分位无获益。

要点

  • GLP-1RA整体降低2型糖尿病肾脏结局风险,HR 0.84 [0.72-0.97]。
  • KFRE最高风险四分位绝对风险降低-2.76%,最低四分位无获益。
  • 基线eGFR低、eGFR下降快、白蛋白尿高者更可能获益。

核心结论

  • GLP-1RA治疗在2型糖尿病中带来异质性肾脏获益,某些高风险亚组风险降低最大。
  • 研究结果支持基于肾功能/损伤、eGFR下降轨迹和KFRE风险分层进行个体化GLP-1RA处方。

研究设计与样本

  • 采用目标试验模拟框架的新使用者、活性对照队列研究,纳入斯德哥尔摩2008-2021年起始GLP-1RA或DPP-4i的2型糖尿病患者超过28,000例。
  • 最终分析纳入11,772例GLP-1RA起始者和16,775例DPP-4i起始者。
  • 使用肾脏衰竭风险方程(KFRE)风险建模和因果生存森林效应建模评估异质性治疗效果,并用Shapley Additive Explanations识别驱动获益的临床特征。

主要发现

  • 与DPP-4i相比,GLP-1RA起始与五年肾脏结局风险降低相关(风险差-0.72% [95%CI -1.53至0.13];HR 0.84 [0.72-0.97])。
  • KFRE最高风险四分位患者绝对风险降低显著(-2.76% [95%CI -5.60至-0.08];HR 0.70 [0.56-0.86]),最低四分位无获益。
  • 效应建模对比第四四分位与第一四分位(HR 0.79 [0.65-0.94] vs. 1.06 [0.54-1.74])。
  • 治疗获益的关键预测因素包括较低基线eGFR、较快的前期eGFR下降、较高白蛋白尿、较高糖化血红蛋白以及治疗开始前较多医疗资源使用。

临床怎么用

  • 临床可依据肾功能/损伤(eGFR、白蛋白尿)、eGFR下降轨迹和KFRE风险分层来个体化选择GLP-1RA治疗。
  • 对KFRE高风险四分位患者,GLP-1RA的肾脏绝对获益更明显,应优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: On average, glucagon-like peptide-1 receptor agonists (GLP-1RA) lower the risk of kidney outcomes in type 2 diabetes, but individual responses may differ. Here, we aimed to identify patient subgroups more likely to derive kidney benefit from GLP-1RA therapy. METHODS: Using a target trial emulation framework, we conducted a new-user, active comparator cohort study that included over 28,000 individuals with type 2 diabetes initiating either GLP-1RA or dipeptidyl peptidase-4 inhibitors (DPP-4i) in Stockholm (2008-2021). Heterogeneous treatment effects on a composite kidney outcome were estimated using complementary approaches: risk modelling with the kidney failure risk equation (KFRE) and effect modelling with causal survival forests. For interpretability, Shapley Additive Explanations identified clinical features driving benefit. RESULTS: We included 11,772 GLP-1RA and 16,775 DPP-4i initiators. Compared with DPP-4i, GLP-1RA initiation was associated with a lower five-year risk of kidney outcomes (risk difference -0.72% [95% confidence interval -1.53 to 0.13]; hazard ratio [HR] 0.84 [0.72-0.97]). Risk modelling revealed pronounced heterogeneity: patients in the highest KFRE-risk quarter experienced a substantial absolute risk reduction (-2.76% [-5.60 to -0.08]; HR 0.70 [0.56-0.86]), whereas those in the lowest quarter showed no benefit. Effect modelling similarly contrasted quarters 4 vs. 1 (HR 0.79 [0.65-0.94] vs. 1.06 [0.54-1.74]). Key predictors of treatment benefit included lower baseline estimated glomerular filtration rate (eGFR), faster preceding eGFR decline, higher albuminuria, higher glycated hemoglobin, and greater healthcare utilization prior to treatment start. CONCLUSIONS: GLP-1RA therapy confers heterogeneous kidney benefits in type 2 diabetes, with certain high-risk subgroups experiencing the largest risk reduction. Such findings support personalized GLP-1RA prescribing guided by kidney function/damage, trajectories of eGFR decline, and KFRE risk stratification.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Xu Y, Maas CCHM, Huang T, et al. Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes. Kidney Int. 2026. PMID: 42498061. doi:10.1016/j.kint.2026.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。